Maclay John D, McAllister David A, Mills Nicholas L, Paterson Finny P, Ludlam Christopher A, Drost Ellen M, Newby David E, Macnee William
Centre for Inflammation Research, Edinburgh University, Edinburgh, United Kingdom.
Am J Respir Crit Care Med. 2009 Sep 15;180(6):513-20. doi: 10.1164/rccm.200903-0414OC. Epub 2009 Jun 19.
Cardiovascular disease is a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD), which may in part be attributable to abnormalities of systemic vascular function. It is unclear whether such associations relate to the presence of COPD or prior smoking habit.
To undertake a comprehensive assessment of vascular function in patients with COPD and healthy control subjects matched for smoking history.
Eighteen men with COPD were compared with 17 healthy male control subjects matched for age and lifetime cigarette smoke exposure. Participants were free from clinically evident cardiovascular disease.
Pulse wave velocity and pulse wave analysis were measured via applanation tonometry at carotid, radial, and femoral arteries. Blood flow was measured in both forearms using venous occlusion plethysmography during intrabrachial infusion of endothelium-dependent vasodilators (bradykinin, 100-1,000 pmol/min; acetylcholine, 5-20 microg/min) and endothelium-independent vasodilators (sodium nitroprusside, 2-8 microg/min; verapamil, 10-100 microg/min). Tissue plasminogen activator (t-PA) was measured in venous plasma before and during bradykinin infusions. Patients with COPD have greater arterial stiffness (pulse wave velocity, 11 +/- 2 vs. 9 +/- 2 m/s; P = 0.003; augmentation index, 27 +/- 10 vs. 21 +/- 6%; P = 0.028), but there were no differences in endothelium-dependent and -independent vasomotor function or bradykinin-induced endothelial t-PA release (P > 0.05 for all).
COPD is associated with increased arterial stiffness independent of cigarette smoke exposure. However, this abnormality is not explained by systemic endothelial dysfunction. Increased arterial stiffness may represent the mechanistic link between COPD and the increased risk for cardiovascular disease associated with this condition.
心血管疾病是慢性阻塞性肺疾病(COPD)患者发病和死亡的主要原因,这可能部分归因于全身血管功能异常。目前尚不清楚这些关联是与COPD的存在还是既往吸烟习惯有关。
对COPD患者和匹配吸烟史的健康对照者的血管功能进行全面评估。
将18名患有COPD的男性与17名年龄和终生吸烟暴露量相匹配的健康男性对照者进行比较。参与者无临床明显的心血管疾病。
通过在颈动脉、桡动脉和股动脉处使用压平式眼压计测量脉搏波速度和脉搏波分析。在肱动脉内输注内皮依赖性血管舒张剂(缓激肽,100 - 1000 pmol/min;乙酰胆碱,5 - 20 μg/min)和内皮非依赖性血管舒张剂(硝普钠,2 - 8 μg/min;维拉帕米,10 - 100 μg/min)期间,使用静脉阻塞体积描记法测量双侧前臂的血流量。在缓激肽输注前和输注期间测量静脉血浆中的组织纤溶酶原激活物(t-PA)。COPD患者的动脉僵硬度更高(脉搏波速度,11 ± 2 vs. 9 ± 2 m/s;P = 0.003;增强指数,27 ± 10 vs. 21 ± 6%;P = 0.028),但内皮依赖性和非依赖性血管舒缩功能或缓激肽诱导的内皮t-PA释放没有差异(所有P > 0.05)。
COPD与独立于吸烟暴露的动脉僵硬度增加有关。然而,这种异常不能用全身内皮功能障碍来解释。动脉僵硬度增加可能代表COPD与这种疾病相关的心血管疾病风险增加之间的机制联系。